BR112012000421A2 - composições e métodos para intensificar a produção de um produto biológico. - Google Patents

composições e métodos para intensificar a produção de um produto biológico.

Info

Publication number
BR112012000421A2
BR112012000421A2 BR112012000421A BR112012000421A BR112012000421A2 BR 112012000421 A2 BR112012000421 A2 BR 112012000421A2 BR 112012000421 A BR112012000421 A BR 112012000421A BR 112012000421 A BR112012000421 A BR 112012000421A BR 112012000421 A2 BR112012000421 A2 BR 112012000421A2
Authority
BR
Brazil
Prior art keywords
enhancing
compositions
production
methods
biological product
Prior art date
Application number
BR112012000421A
Other languages
English (en)
Inventor
Rossomando Anthony
Bettencourt Brian
Kocisko David
Hinkle Greg
M Maraganore John
Manoharan Muthian
Hogan Shannon
Pollard Stuart
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of BR112012000421A2 publication Critical patent/BR112012000421A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112012000421A 2009-07-06 2010-07-06 composições e métodos para intensificar a produção de um produto biológico. BR112012000421A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US22337009P 2009-07-06 2009-07-06
US24486809P 2009-09-22 2009-09-22
US26741909P 2009-12-07 2009-12-07
US29398010P 2010-01-11 2010-01-11
US31958910P 2010-03-31 2010-03-31
US33439810P 2010-05-13 2010-05-13
US35493210P 2010-06-15 2010-06-15
PCT/US2010/041099 WO2011005786A2 (en) 2009-07-06 2010-07-06 Compositions and methods for enhancing production of a biological product

Publications (1)

Publication Number Publication Date
BR112012000421A2 true BR112012000421A2 (pt) 2019-09-24

Family

ID=43429810

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012000421A BR112012000421A2 (pt) 2009-07-06 2010-07-06 composições e métodos para intensificar a produção de um produto biológico.

Country Status (6)

Country Link
US (1) US20140099666A1 (pt)
EP (1) EP2451823A4 (pt)
JP (1) JP2014501097A (pt)
BR (1) BR112012000421A2 (pt)
CA (1) CA2767225A1 (pt)
WO (1) WO2011005786A2 (pt)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
EP3296398A1 (en) * 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
AU2014280918B2 (en) * 2009-12-18 2016-11-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat HSF1-related diseases
EP3000885B1 (en) 2009-12-18 2018-07-25 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat hsf1-related diseases
US20120191434A1 (en) * 2010-08-25 2012-07-26 Gt Life Sciences, Inc. Articles of manufacture and methods for modeling chinese hamster ovary (cho) cell metabolism
WO2012177639A2 (en) * 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
WO2013067050A1 (en) 2011-10-31 2013-05-10 University Of Utah Research Foundation Genetic alterations in glioblastoma
WO2013102155A1 (en) * 2011-12-29 2013-07-04 Cell Machines, Inc. Cells for virus and protein production
EP2831232A4 (en) 2012-03-30 2015-11-04 Univ Washington METHOD FOR MODULATING TAU EXPRESSION TO REDUCE PROBLEMS AND MODIFY A NEURODEGENERATIVE SYNDROME
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
EA201492116A1 (ru) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии mecp2
SG11201407483YA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating smn gene family expression
PL2922554T3 (pl) * 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
AU2013374345A1 (en) 2013-01-17 2015-08-06 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
CN105264091B (zh) 2013-03-14 2020-02-28 Ionis制药公司 用于调节tau表达的组合物和方法
DK2992098T3 (da) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
TW202246503A (zh) 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
EP2865758A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
KR20220013460A (ko) * 2014-03-04 2022-02-04 시그마-알드리치 컴퍼니., 엘엘씨 바이러스 내성 세포 및 이의 용도
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
RU2716991C2 (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
WO2016077687A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
EP3355924A1 (en) 2015-09-29 2018-08-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of treating and preventing amyotrophic lateral sclerosis
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
EP3362564B1 (en) * 2015-10-14 2020-07-01 Aquinnah Pharmaceuticals, Inc. Nucleic acid based tia-1 inhibitors
WO2017075335A1 (en) 2015-10-28 2017-05-04 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
KR102427379B1 (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
US11710048B2 (en) 2016-07-05 2023-07-25 Samsung Electronics Co., Ltd. Method and device for assessing feasibility of biochemical reaction in organism
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
HUE065170T2 (hu) 2016-09-29 2024-05-28 Biogen Ma Inc Vegyületek és módszerek a TAU expresszió csökkentésére
KR101837855B1 (ko) 2016-10-18 2018-03-13 단국대학교 산학협력단 뎅기바이러스 혈청형 2의 메틸트랜스퍼라제 활성을 억제하는 rna 앱타머
WO2018073365A1 (en) * 2016-10-19 2018-04-26 F. Hoffmann-La Roche Ag Method for producing an immunoconjugate
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JP2020518258A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
EP3697908A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
EP3719127A4 (en) 2017-12-01 2021-10-20 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE
CN110944675B9 (zh) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CA3083970A1 (en) 2017-12-01 2019-06-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
EP3719126B1 (en) 2017-12-01 2025-01-01 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
DK3719128T3 (da) 2017-12-01 2025-03-03 Suzhou Ribo Life Science Co Ltd Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf
WO2019115417A2 (en) * 2017-12-12 2019-06-20 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating rb1 expression
AU2018394875B2 (en) 2017-12-29 2023-08-03 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
EP3762500A1 (en) 2018-03-06 2021-01-13 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
EP3775211B1 (en) * 2018-04-12 2023-04-05 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
KR20210019996A (ko) 2018-05-15 2021-02-23 보이저 테라퓨틱스, 인크. 파킨슨병의 치료를 위한 조성물 및 방법
US20210214749A1 (en) 2018-05-16 2021-07-15 Voyager Therapeutics, Inc. Directed evolution
US20210207167A1 (en) 2018-05-16 2021-07-08 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
WO2020007702A1 (en) * 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting bcl2l11
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US20210254103A1 (en) 2018-07-02 2021-08-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
CN112770812A (zh) 2018-07-24 2021-05-07 沃雅戈治疗公司 产生基因治疗制剂的系统和方法
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
EP3628735A1 (en) * 2018-09-25 2020-04-01 Centre National De La Recherche Scientifique Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
WO2020072849A1 (en) 2018-10-04 2020-04-09 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
US20210371470A1 (en) 2018-10-12 2021-12-02 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
GB201817971D0 (en) 2018-11-02 2018-12-19 British American Tobacco Investments Ltd Method
EP3877408A4 (en) * 2018-11-06 2022-08-24 University of Miami COMPOSITIONS AND PRODUCTION OF RECOMBINANT AAV VIRUS VECTORS CAPABLE OF IN VIVO GLYCOENGINEERING
WO2020135673A1 (zh) 2018-12-28 2020-07-02 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
SG11202107645RA (en) 2019-01-18 2021-08-30 Voyager Therapeutics Inc Methods and systems for producing aav particles
CN109852648B (zh) * 2019-04-11 2022-08-09 广西大学 酶法制备右旋糖酐硒聚物的方法
CN110117607A (zh) * 2019-04-29 2019-08-13 贵州大学 一种玉米黑粉菌效应蛋白Pit2基因的重组载体和表达方法
EP3962536A1 (en) 2019-04-29 2022-03-09 Voyager Therapeutics, Inc. Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
CN114375336A (zh) * 2019-05-07 2022-04-19 伯尔尼大学 用于抑制细胞中pros1表达的核酸
US11162102B2 (en) 2019-05-13 2021-11-02 Dna Twopointo Inc. Modifications of mammalian cells using artificial micro-RNA to alter their properties and the compositions of their products
KR20220011689A (ko) 2019-05-22 2022-01-28 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도
AU2020280439B2 (en) 2019-05-22 2025-08-14 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
US12590304B2 (en) 2019-05-22 2026-03-31 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
CN113795582B (zh) 2019-05-24 2024-05-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
EP4010465A1 (en) 2019-08-09 2022-06-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
EP4022070A1 (en) 2019-08-26 2022-07-06 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US12534688B2 (en) * 2019-10-07 2026-01-27 Conopco, Inc. Fabric softener composition comprising a betaine ester and a fatty co-softener
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
WO2022032153A1 (en) 2020-08-06 2022-02-10 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2022032282A1 (en) * 2020-08-06 2022-02-10 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Methods and reagents for microbiome analysis
IL290590A (en) * 2020-08-14 2022-04-01 Univ Massachusetts Cell culture methods
WO2022051627A2 (en) * 2020-09-04 2022-03-10 Dna Twopointo Inc. Modifications of mammalian cells using artificial micro-rna to alter their properties and the compositions of their products
IT202000023647A1 (it) * 2020-10-07 2022-04-07 Univ Degli Studi Padova Sirna nel trattamento della sindrome ectrodattilia-displasia ectodermica-palatoschisi (eec)
CN112430625B (zh) * 2020-11-23 2022-08-05 武汉枢密脑科学技术有限公司 含有变异猪伪狂犬病病毒gD蛋白基因的重组腺相关病毒转移载体、病毒及其制备和应用
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2022187473A2 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
EP4326855A1 (en) * 2021-04-19 2024-02-28 Genentech, Inc. Modified mammalian cells
AU2022286964A1 (en) * 2021-06-02 2024-01-18 Sivec Biotechnologies Llc Bacterial delivery of antibodies, antibody derivatives, and polypeptides to eukaryotic cells
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CN118382697A (zh) * 2021-12-17 2024-07-23 豪夫迈·罗氏有限公司 能够增加葡糖脑苷脂酶表达的寡核苷酸
CN114317511B (zh) * 2022-03-10 2022-06-14 北京爱普益医学检验中心有限公司 蛋白、基因、重组载体、表达盒、宿主及用途
AU2023250231A1 (en) * 2022-04-08 2024-10-31 Scineuro Therapeutics Inc. Oligonucleotide for reducing the expression of leucine-rich repeat kinase 2 (lrrk2) and its use for preventing and/or treating human diseases
GB202208022D0 (en) * 2022-05-31 2022-07-13 Sisaf Ltd Therapeutic compounds and compositions
CN116064398A (zh) * 2022-07-04 2023-05-05 上海倍谙基生物科技有限公司 定点同步敲入和敲除基因的抗凋亡细胞改造方法及其应用
US20260085328A1 (en) 2022-09-08 2026-03-26 Voyager Therapeutics, Inc. Controlled expression of viral proteins
KR20250129743A (ko) 2022-12-29 2025-08-29 보이저 테라퓨틱스, 인크. Mapt를 조절하기 위한 조성물 및 방법
WO2024165571A2 (en) * 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
CN116218762B (zh) * 2023-03-13 2025-08-29 深圳市中医院 肾小管类器官培养基及应用、肾小管类器官的培养方法
EP4735602A2 (en) 2023-06-27 2026-05-06 Atrium Therapeutics, Inc. Compositions and methods of using prkag2-targeting antibody-oligonucleotide conjugates abstract
CN116855497B (zh) * 2023-07-10 2025-09-12 暨南大学 一种抑制人USP46基因表达的siRNA和脂质体及其应用
CN117344061B (zh) * 2023-12-05 2024-02-27 云南省细胞质量检测评价中心有限公司 一种同时检测五种人源病毒ebv、hbv、hcv、hiv、hpv的方法、试剂盒、引物和探针及其应用
WO2025125576A2 (en) * 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) * 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025235441A1 (en) * 2024-05-08 2025-11-13 Vanderbilt University Overexpressing nsun2 to generate super producer cell line

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517644B1 (en) * 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
WO2002072762A2 (en) * 2001-03-08 2002-09-19 Advanced Cell Technology, Inc. Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture
KR100434118B1 (ko) * 2001-09-17 2004-06-04 한국과학기술원 카스파제-3에 대한 안티센스 뉴클레오타이드, 그의발현벡터 및 이를 이용한 세포예정사의 억제방법
US20090023670A1 (en) * 2006-05-19 2009-01-22 Sebestyen Magdolna G Regulation of Transgene Expression by RNA Interference
JP2010507394A (ja) * 2006-10-24 2010-03-11 トルービオン ファーマスーティカルズ インコーポレイテッド 改良免疫糖タンパク質のための物質および方法
WO2009012173A2 (en) * 2007-07-13 2009-01-22 Dharmacon, Inc. Enhanced biotherapeutic production using inhibitory rna

Also Published As

Publication number Publication date
CA2767225A1 (en) 2011-01-13
WO2011005786A2 (en) 2011-01-13
JP2014501097A (ja) 2014-01-20
WO2011005786A3 (en) 2011-03-24
EP2451823A2 (en) 2012-05-16
US20140099666A1 (en) 2014-04-10
EP2451823A4 (en) 2013-07-03

Similar Documents

Publication Publication Date Title
BR112012000421A2 (pt) composições e métodos para intensificar a produção de um produto biológico.
BRPI1013426A2 (pt) organismos para produção de 1,3-butanodiol
BRPI1010581A2 (pt) micro-organismos para a produção de 1,4-butanodiol e métodos relacionados
BRPI1012525A2 (pt) composições de nanopatículas isentas de príons e métodos para sua fabricação
HUE058971T2 (hu) RSV F fehérjekészítmények és eljárások azok elõállítására
BRPI1013822A2 (pt) Método para síntese de um trissacarídeo.
BR112012003365A2 (pt) método e dispositivo para a fabricação de objetos de titânio.
BRPI0908130A2 (pt) Produto
BRPI0925037A2 (pt) Composição contendo piceatanol e método de produzir a composição contendo piceatanol.
BRPI1012875A2 (pt) composições farmacêuticas sólidas e processos para sua produção
BRPI1011336A2 (pt) material de produção de embalagem
IT1393352B1 (it) Apparato di aliquotazione di contenitori di materiale biologico.
GB0904214D0 (en) Biological products
BRPI0913232A2 (pt) Produto alimentício
BRPI1011338A2 (pt) material de produção de embalagem
FI20085767L (fi) Kipsituote
BRPI1014090A2 (pt) produto de bebida instantânea
FI20095500A0 (fi) Tuote ja menetelmä sen valmistamiseksi
BRPI1010735A2 (pt) composição para a produção de um fungicida e um bactericida biológico
BR112012001731A2 (pt) Processo para a preparação de 1-benzil-3-hidroximetil-1h-indazol
GB0900425D0 (en) Biological products
BR112012025490A2 (pt) ''método para produção de 1,5 oebtanodiamina''
PT2509443E (pt) Produto alimentar gelificado
FR2944023B1 (fr) Procede de preparation de superplastifiants.
ITTO20110857A1 (it) Procedimento per la produzione di cicloesanonossina.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.